BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that Leqembi sales are expected to total JPY 76.5 billion (approximately SEK 5.1 billion) for their fiscal year (FY) 2025 ...

STOCKHOLM, May 15, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that Leqembi sales are expected to total JPY 76.5 billion (approximately SEK ...

Zeit Aktuelle Nachrichten 06:00 BioArctic AB: Eisai projects Leqembi revenue to total JPY 76.5 billion for fiscal year 2025 (April 2025 - March 2026) Stockholm, Sweden, May 15, 2025 - BioArctic AB ...

Other options to detect Alzheimer's include procedures such as a spinal tap, which requires an invasive puncture to collect ...

The drop in GPM is likely due to the increasing proportion of sales from Leqembi, one of Eisai’s products. The company’s guidance for current-year sales of ¥790 billion, which is the same as last year ...

The FDA has approved the first blood test for Alzheimer's disease based on a blood test – from Fujirebio – in a step forward ...